Summary The prognostic role of drug-induced amenorrhea (DIA) was restrospectively evaluated in 221 out of 254 consecutive premenopausal patients treated with adjuvant CMF or a CMF-containing regimen; 33 patients were eliminated because of lack of menstrual data. All patients had metastatic axillary nodes; drug regimens were: CMF x 9 courses ± Tamoxifen (TM) and CMF x 6 courses; median age was 43 (range 26-54 
Adjuvant chemotherapy, especially cyclophosphamide, methotrexate and 5-fluorouracil (CMF), has been shown to significantly increase disease-free survival and overall survival of premenopausal patients with operable breast cancer (Bonadonna et al., 1985; Early Breast Cancer Trialists' Collaborative Group, 1988) .
In similar groups of patients, surgical oophorectomy and ovarian radiation, as adjuvant to mastectomy, were also effective in reducing relapses and deaths (Nissen-Meyer, 1967; Bryant et al., 1981; Meakin et al., 1983) .
Since cytotoxic chemotherapy is more effective in premenopausal than in postmenopausal patients (Early Breast Cancer Trialists' Collaborative Group, 1988) and, in many cases, it induces ovarian failure with the occurrence of amenorrhea, a question arises about the relationship between the effect of adjuvant chemotherapy and the development of amenorrhea. In fact it has been suggested that drug-induced amenorrhea has beneficial therapeutic significance and that the effect of adjuvant chemotherapy is mediated, at least partly, through the suppression of endogenous hormone production.
While an association between drug-induced amenorrhea and longer disease free survival has been found by several authors in premenopausal patients with early breast cancer (Ludwig Breast Cancer Study Group, 1985; Padmanabhan et al., 1986; Brincker et al., 1987; Tormey et al., 1990) , others have failed to do so (Bonadonna et al., 1985; Fisher et al., 1979) , and thus the question remains still open (Editorial, 1989) .
The aim of our study was to evaluate, restrospectively, if the development of drug-induced amenorrhea is associated with a prolongation of DFS in a series of consecutive cases of homogeneous premenopausal, node-positive patients with early breast cancer, treated with adjuvant CMF-containing regimens between 1978 and 1989.
Patients and methods

Selection criteria
The study included premenopausal women Sixty-eight percent of patients were enrolled in two controlled clinical trials; one of which has been previously reported (Bianco et al., 1988 (Mantel, 1966) . In studying amenorrhea, life-time analyses were performed taking into account the transient nature of the menstrual status: cessations of menses, indeed, as consequence of the therapy, do arise at a sometime after the starting of the treatment. Thus, a potential temporal bias exists in classifying a subject as amenorrheic or not, since the length of disease-free follow up could affect the chance of amenorrhea to be induced (Anderson et al., 1983) . Even though the magnitude of the bias is likely to be small, because most of DIA occur shortly after the therapy, an appropriate analysis was performed using a method first published by Mantel and Byar (1974) , in which subjects (amenorrhea yes/no) are compared according to their response status at each time of the follow up. Graphical representation of DFS curves was made according to Simon and Makuch (1984) : non relapsed subjects at a given arbitrary time-origin to. from the beginning of follow up, are classified in two groups according to whether they have or have not experienced DIA before to. For the non amenorrheic group, DFS curve estimates the probability of not relapsing beyond any time tj, greater than t., conditional upon being in NA status at to; subjects who eventually became amenorrheic are censored at the time they cross to the DIA group. For amenorrheic ('responders') patients, DFS curve estimates the probability of not relapsing beyond tj, tj>t., given either they are in DIA status at to or enter it in the interval between to and tj. As suggested by Simon and Makuch, in our study, to was fixed at 12 weeks after the onset of therapy, when more than half of patients had experienced DIA. For example, a patient who develops amenorrhea at 8 weeks is always considered to have been amenorrheic, from the 12th week (to) until relapse or last follow up. Conversely a patient who becomes amenorrheic at 36 weeks remains in the non-amenorrheic group from 12 weeks (to) to 36 weeks, when she is censored. This same patient is then considered in the amenorrheic group from the time of development of amenorrhea until relapse or last follow up. In the 'landmark' method (Anderson et al., 1983) , instead, groups are defined according to the menstrual status at a given 'landmark' time to, regardless of any subsequent variation during the follow up. In our study no relapse was observed before to time; therefore no patient was excluded from the computations.
Multivariate adjustment for other baseline prognostic factors was performed by a Cox's regression model (Cox, 1972) , where amenorrhea (yes/no) was entered as a time-dependent covariate (BMDP, 1988 (Table II) .
A significant correlation was also found between the development of amenorrhea and the patient's age: the younger the patients the lower the incidence of DIA. Among amenorrheic patients a decreasing percentage of temporary DIA was observed with increasing age. Furthermore, an inverse linear correlation (Figure 1 ) was observed between the patient's age and the time required to produce amenorrhea (r = -0.42; P < 0.001).
One hundred and two relapses were observed during the follow up.
DFS of amenorrheic patients was significantly better than that of patients who maintained normal menses (MantelByar chi-square = 10.95, P< 0.001; relative hazard = 0.50). DFS curves for DIA and NA patients, as shown in Figure 2 , take into account the time-dependent nature of menstrual status according to Simon and Makuch. Time- fined. Some studies (Bonadonna et al., 1985; Padmanabhan et al., 1986; Tormey et al., 1990 ) used a rather wide criterion to define premenopause which included women without menstrual activity up to 12 months. The Ludwig Breast Cancer Study Group (1985) evaluated the role of DIA in patients who had their last menses within 6 months prior to initiation of chemotherapy; however, a similar DFS was observed in the subgroup of patients who had their last menses within 6 weeks prior to beginning of adjuvant chemotherapy. In order to ensure that amenorrhea was drug-induced rather than physiologic we adopted a restrictive criterion to define premenopausal status such as the occurrence of the last normal menses within the 6 weeks preceding the beginning of therapy.
Another important aspect is the definition of DIA. We believe that, in order to consider amenorrhea as drug-related, this definition should be inclusive of both a minimum duration of the amenorrhea itself and a defined period of its onset from the end of the therapy. While data are lacking on the latter question, there is a general concordance (Fisher et al., 1979; Bonadonna et al., 1985; Ludwig Breast Cancer Study Group, 1985; Padmanabhan et al., 1986; Brincker et al., 1987) in defining DIA as cessation of menses for at least 3 months, except for the Eastern Cooperative Oncology Group (ECOG) study (Tormey et al., 1990) in which drug-related amenorrhea is defined as 12 months without menstrual activity.
In our study, as well as in others (Fisher et al., 1979; Bonadonna et al., 1985; Ludwig Breast Cancer Study Group, 1985; Padmanabhan et al., 1986; Tormey et al., 1990 ), a close relationship between induction of amenorrhea and age of the patient is evident, the older the patient the greater the incidence of DIA. Furthermore, we observed an inverse correlation between the time to onset of DIA and patient's age. These results seem to be the signal of the increasing ovarian sensitivity to cyclophosphamide in older women approaching to physiological menopause, as suggested by Rose and Davis (1980 (Fisher et al., 1979; Bonadonna et al., 1985; Ludwig Breast Cancer Study Group, 1985; Padmanabhan et al., 1986; Brincker et al., 1987; Tormey et al., 1990 Cancer Study Group (1985) dealt with this question, with similar results.
Finally, the time dependent nature of amenorrhea might somehow affect the correlation between DIA and DFS (Anderson et al., 1983) . This potential bias, however, is probably small because of the general early occurrence of cessation of menses following initiation of therapy. To overcome this bias, in our study, we employed the Mantel-Byar procedure (Mantel & Byar, 1974) in univariate analysis and the Cox proportional hazard regression model (Cox, 1972) in which amenorrhea is a time varying covariate, as it was done in the ECOG study (Tormey et al., 1990) . The relationship between DIA and length of DFS was analysed in several studies with conflicting results.
In the Milan trial (Bonadonna et al., 1985) only patients younger than 41 were analysed for DFS as related to DIA, since only two patients older than 40 maintained normal menses. Thus, analysis was carried out on a small number of cases, i.e. 19 non amenorrheic and 13 amenorrheic patients, and the conclusion was that DFS was not affected by DIA. The 10 year DFS was 31.6% and 37.2% for the two groups, respectively. In addition, the same authors reported that salvage castration at first relapse induced a higher response rate in patients who had experienced DIA as compared to those who had not (30% vs 20% response rate). Based upon these findings they concluded that DIA is not equivalent to complete ovarian failure; this opinion, based on a low number of events, is contrasting with the data of others who assessed ovarian function by measuring levels of circulating sexual hormones during adjuvant chemotherapy (Koyama et al., 1977; Fisher et al., 1979; Rose & Davis, 1980; Ludwig Breast Cancer Study Group, 1985; Padmanabhan et al., 1987) , including ourselves (Delrio et al., 1986) .
The National Surgical Adjuvant Breast Project group (Fisher et al., 1979) Similarly, in the ECOG trial (Tormey et al., 1990) patients developing DIA during adjuvant therapy with CMF, CMFP or CMFPT had a highly significant better survival. The Danish Breast Cancer Cooperative Group (Brincker et al., 1987) found, in a prospective randomised trial, that cyclophosphamide alone was effective in improving DFS only in patients who experienced DIA, differently from CMF which was active in DIA as well as in NA patients. It was suggested that the effect of chemotherapy could be mediated partly through ovarian suppression and partly through a purely cytotoxic mechanism, the latter being more evident when combination chemotherapy (CMF) was used.
Finally, in 1986, the Manchester group (Padmanabhan et al., 1986) reported, in a randomised trial comparing CMF with observation, that a significant improvement of 3-year DFS and OS was seen only in premenopausal patients who experienced CMF induced permanent amenorrhea: DFS of CMF-treated non amenorrheic patients was similar to that of untreated controls. However, recently the same group reported in abstract form (Richards et al., 1990 ) that, at the 8-year update of the study, the importance of DIA, in patients younger than 41, has lessened. Since a full-length paper is not available, it is difficult to discuss this result. Our data show the existence of a significant correlation between DIA and prolongation of DFS. The prognostic relevance of DIA is independent of number of positive nodes, tumour size and number of CMF cycles. These results are consistent with those reported by the majority of studies that could adequately document amenorrhea.
Although the existence of a strong statistical association does not necessarily mean that DIA is causally related to a better prognosis in early breast cancer, and amenorrhea might only be a marker of a greater chemotherapy-induced tumour cell kill (International Breast Cancer Study Group, 1990) , our results strongly suggest that the suppression of ovarian function could play a relevant role in the mechanism of action of adjuvant cytotoxic therapy in premenopausal breast cancer patients.
The beneficial effect of oophorectomy in both advanced and early disease, the recent results with LHRH analogues, which produce complete suppression of ovarian function, in patients with advanced disease, the relationship between DIA and improved DFS could suggest that adjuvant hormonotherpay, e.g. LHRH superagonist ± Tamoxifen, might have some effect in premenopausal patients. However, there is no evidence that the effect of endocrine therapies will be as large as chemotherapy. In fact, a recent paper of the International Breast Cancer Study Group (Goldhirsch et al., 1990) shows that chemotherapy provides additional cytotoxic effect over and above those attributable to endocrine mechanisms alone. Whether endocrine therapies can replace chemotherapy for subset of premenopausal women with presumably hormoneresponsive primaries is a matter for future clinical trials.
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